Marker Therapeutics MRKR
NASDAQ MRKR
$1.05 +0.00 (+0.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

Marker Therapeutics (MRKR) Income from Discontinued Operations (2022 - 2023)

Updated

Marker Therapeutics (MRKR) recorded Income from Discontinued Operations of -$62,939 in Q4 2023, compared with -$813,062 a year earlier.

Analysis

Marker Therapeutics (MRKR) Income from Discontinued Operations (2022 - 2023) Analysis & Trends

For FY2023, Marker Therapeutics reported Income from Discontinued Operations of $5.81 million.

  • Across earlier years, Income from Discontinued Operations came in at -$10.15 million in FY2022.
  • Quarterly Income from Discontinued Operations has ranged from -$4.01 million in Q2 2022 to $6.61 million in Q2 2023 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Discontinued) (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn -
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn -
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn -
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn -
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn -
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 8.00 Mn
10 Marker Therapeutics 17.53 Mn -42.37 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -62,939.00
Jun 30, 2023 6.61 Mn
Mar 31, 2023 -742,751.00
Dec 31, 2022 -813,062.00
Sep 30, 2022 -1.19 Mn
Jun 30, 2022 -4.01 Mn
API Access

Marker Therapeutics Income from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-discontinued-operations&ticker=MRKR&period=max&api_key=YOUR_API_KEY